EA200501426A1 - Производные эстрогена в качестве ингибиторов стероидной сульфатазы - Google Patents

Производные эстрогена в качестве ингибиторов стероидной сульфатазы

Info

Publication number
EA200501426A1
EA200501426A1 EA200501426A EA200501426A EA200501426A1 EA 200501426 A1 EA200501426 A1 EA 200501426A1 EA 200501426 A EA200501426 A EA 200501426A EA 200501426 A EA200501426 A EA 200501426A EA 200501426 A1 EA200501426 A1 EA 200501426A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
steroid
estrogen
derivatives
ryavlyaetsya
Prior art date
Application number
EA200501426A
Other languages
English (en)
Other versions
EA011123B1 (ru
Inventor
Маттью Лис
Алан Пурохит
Майкл Джон Рид
Саймон Пол Ньюман
Суриндер Кумар Чандер
Фабрис Журден
Барри Виктор Ллойд Поттер
Original Assignee
Стерикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0306717A external-priority patent/GB0306717D0/en
Priority claimed from GB0315885A external-priority patent/GB0315885D0/en
Application filed by Стерикс Лимитед filed Critical Стерикс Лимитед
Publication of EA200501426A1 publication Critical patent/EA200501426A1/ru
Publication of EA011123B1 publication Critical patent/EA011123B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Abstract

Объектом настоящего изобретения является соединение, включающее стероидную циклическую систему и необязательную группу R, выбранную среди гидроксигруппы, сульфаматной группы, фосфонатной группы, тиофосфонатной группы, сульфогруппы или сульфонамидной группы, в котором цикл D, входящий в стероидную циклическую систему, замещен группой Rформулы -L-R, где L является необязательной мостиковой группой, а Rвыбрана среди групп, являющихся нитрильной группой, спиртом, сложным эфиром, простым эфиром, амином и алкеном или включающих одну из перечисленных групп, при том условии, что когда Rявляется спиртом или включает его, L наличествует, и в котором цикл А, принадлежащий к стероидной циклической системе, замещен по положению 2 или 4 группой R, где Rявляется гидрокарбильной группой.
EA200501426A 2003-03-24 2004-02-20 Производные эстрогена в качестве ингибиторов стероидной сульфатазы EA011123B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0306717A GB0306717D0 (en) 2003-03-24 2003-03-24 Compound
GB0315885A GB0315885D0 (en) 2003-07-07 2003-07-07 Compound
PCT/GB2004/000705 WO2004085459A1 (en) 2003-03-24 2004-02-20 Oestrogen derivatives as inhibitors of steroid sulphatase

Publications (2)

Publication Number Publication Date
EA200501426A1 true EA200501426A1 (ru) 2006-06-30
EA011123B1 EA011123B1 (ru) 2008-12-30

Family

ID=33099976

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501426A EA011123B1 (ru) 2003-03-24 2004-02-20 Производные эстрогена в качестве ингибиторов стероидной сульфатазы

Country Status (15)

Country Link
US (1) US7893284B2 (ru)
EP (1) EP1608671B1 (ru)
JP (1) JP4719144B2 (ru)
AT (1) ATE454395T1 (ru)
AU (1) AU2004224053B2 (ru)
BR (1) BRPI0408703A (ru)
CA (1) CA2520142C (ru)
DE (1) DE602004024966D1 (ru)
DK (1) DK1608671T3 (ru)
EA (1) EA011123B1 (ru)
ES (1) ES2339450T3 (ru)
HK (1) HK1082258A1 (ru)
MX (1) MXPA05010339A (ru)
PL (1) PL378577A1 (ru)
WO (1) WO2004085459A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
WO2008090517A2 (en) * 2007-01-26 2008-07-31 Piramal Life Sciences Limited Enriched plant extract, compound, and methods for the treatment of proliferative disorders
EP2149371A1 (en) 2008-07-28 2010-02-03 PregLem S.A. Use of steroid sulfatase inhibitors for the treatment of preterm labor
WO2010024930A2 (en) * 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
JP2012524778A (ja) * 2009-04-22 2012-10-18 プレジデント アンド フェロウズ オブ ハーバード カレッジ 血管新生阻害剤
WO2012116290A2 (en) * 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
BR112015014397B1 (pt) 2012-12-18 2021-02-02 Washington University composto, composição farmacêutica e uso de um composto
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
EP3498725B1 (en) 2013-04-17 2021-06-09 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
CN105555277B (zh) 2013-07-19 2022-01-11 萨奇治疗股份有限公司 神经活性类固醇化合物、组合物及其用途
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EA201891279A1 (ru) 2013-12-24 2019-01-31 Президент Энд Феллоус Оф Гарвард Колледж Аналоги кортистатина, их синтез и применения
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN117024502A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
ES2808855T3 (es) 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC
SI3224269T1 (sl) 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3473998A4 (en) * 2016-06-15 2019-07-03 Sony Corporation INFORMATION PROCESSING DEVICE, OBSERVATION SYSTEM, OBSERVATION PROCEDURE AND PROGRAM
JP7049313B2 (ja) 2016-07-11 2022-04-06 セージ セラピューティクス, インコーポレイテッド C17、c20、およびc21置換神経刺激性ステロイドおよびそれらの使用方法
JOP20210293A1 (ar) 2019-05-31 2023-01-30 Sage Therapeutics Inc ستيرويدات ذات فعالية عصبية وتركيبات منها

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US6288050B1 (en) * 1997-07-18 2001-09-11 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331987B (en) * 1997-12-04 2002-11-27 Imperial College Polycyclic sulphamate inhibitors of oestrone sulphatase
US6046186A (en) * 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
AU765386B2 (en) * 1998-06-10 2003-09-18 Sterix Limited Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-(o)-sulphamate for inhibition of estrone sulphatase
WO2000066095A2 (en) * 1999-04-30 2000-11-09 Sterix Limited Use of estrone derivatives as antitumour agents
EP1284272A4 (en) * 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk Estra-1,3,5 (10) -triene
JP2003532737A (ja) * 2000-05-11 2003-11-05 リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド 2位置換プレグナ−1,3,5(10)−トリエン誘導体およびコラン−1,3,5(10)−トリエン誘導体およびそれらの生物活性
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
CA2418479C (en) * 2000-08-18 2007-12-18 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer
WO2002062347A1 (en) 2001-02-05 2002-08-15 Oncology Sciences Corporation Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis
GB0421106D0 (en) * 2004-09-22 2004-10-27 Sterix Ltd Compound

Also Published As

Publication number Publication date
ATE454395T1 (de) 2010-01-15
JP4719144B2 (ja) 2011-07-06
US20060094696A1 (en) 2006-05-04
EP1608671B1 (en) 2010-01-06
DK1608671T3 (da) 2010-05-10
JP2006521335A (ja) 2006-09-21
PL378577A1 (pl) 2006-05-02
ES2339450T3 (es) 2010-05-20
AU2004224053A1 (en) 2004-10-07
EP1608671A1 (en) 2005-12-28
US7893284B2 (en) 2011-02-22
AU2004224053B2 (en) 2011-06-09
CA2520142C (en) 2011-01-04
EA011123B1 (ru) 2008-12-30
DE602004024966D1 (de) 2010-02-25
BRPI0408703A (pt) 2006-03-07
CA2520142A1 (en) 2004-10-07
WO2004085459A1 (en) 2004-10-07
MXPA05010339A (es) 2005-12-14
HK1082258A1 (en) 2006-06-02

Similar Documents

Publication Publication Date Title
EA200501426A1 (ru) Производные эстрогена в качестве ингибиторов стероидной сульфатазы
ES2539430T3 (es) Derivados de metastina y uso de los mismos
TW200806328A (en) One-part hair dye composition
CO6150144A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
EA200801596A1 (ru) Новые 11-бета-гидроксиандроста-4-ен-3-оны
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
NZ595303A (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ES2171040T3 (es) Derivados de esteres hidroxiaceticos y su utilizacion como intermediarios de sintesis.
ES2571483T3 (es) Producto intermedio para producir un éster de ácido sulfónico cíclico
ATE499786T1 (de) Mehrsymbol-signale mit einem anfangssymbol und einem erweiterungsteil
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
DK1644312T3 (da) Fremstilling af derivater af 1,3-diphenylprop-2-en-1-on
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
EA201170654A1 (ru) Композиция кондиционирующего шампуня, содержащая водный кондиционирующий гель
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EA200200819A1 (ru) Кристаллическая форма ii линезолида
EA200800253A1 (ru) Бессывороточная культуральная среда для получения рекомбинантных гонадотропинов
DK1931636T3 (da) Isoquinoliner som IGF-1R-inhibitorer
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EA201170277A1 (ru) Синтез и составы на основе солей изофосфорамидного иприта и его аналогов
EA201290746A1 (ru) Композиция
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
EA200602049A1 (ru) Пролекарства стероидов с андрогенным действием
ME01144B (me) 3-aminociklopentankarboksamidi kao modulatori hemokin receptora

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU